SCHEMBL3294605

SCHEMBL3294605

Cc1ccc(S(=O)(=O)Nc2ncccc2OCc2cc(F)cc(F)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.51
SKP2 Q13309 2/20 0.51
ALDH1A1 P00352 4/20 0.49
PPIA P62937 2/20 0.48
LMNA P02545 3/20 0.46
AR P10275 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP19A1 P11511 1/20 0.44
F2 P00734 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
MAPT P10636 2/20 0.43
AGTR1 P30556 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
SLC40A1 Q9NP59 2/20 0.43
MITF O75030 1/20 0.43
S1PR4 O95977 1/20 0.43
S1PR1 P21453 1/20 0.43
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296693 0.89 FFAR4 (0.52) ALDH1A1PPIALMNAARSMN1; SMN2
SCHEMBL3300175 0.88 FFAR4 (0.46) CKS1BSKP2ALDH1A1PPIALMNA
SCHEMBL3300053 0.88 PPIA (0.46) CKS1BSKP2ALDH1A1PPIALMNA
SCHEMBL3294323 0.87 GLO1 (0.48) ALDH1A1PPIAARKMT2AHPGD
SCHEMBL20628168 0.86 AR (0.59) CKS1BSKP2ALDH1A1PPIALMNA
SCHEMBL3293802 0.86 FFAR1 (0.52) PPIALMNASMN1; SMN2KMT2AMEN1
SCHEMBL20627704 0.83 PPIA (0.53) PPIAARSLC40A1
SCHEMBL3293768 0.83 NPC1 (0.52) ALDH1A1PPIALMNACYP19A1KMT2A
SCHEMBL3291973 0.83 PGR (0.50) ALDH1A1PPIASMN1; SMN2SLC40A1HPGD
SCHEMBL3294918 0.82 AR (0.60) PPIAARCYP19A1SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-21 US disclosed
US-7732442-B2 Chemokine receptor antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 US disclosed
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
EP-1661889-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF CCR5, CCR4, CCR1 CKS1B 1226/4885SKP2 2110/4885ALDH1A1 2497/4885
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof CCR5, CCR4, CCR1 CKS1B 1226/4885SKP2 2110/4885ALDH1A1 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.